Compare ACRS & NL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | NL |
|---|---|---|
| Founded | 2012 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 296.8M |
| IPO Year | 2015 | 1994 |
| Metric | ACRS | NL |
|---|---|---|
| Price | $4.34 | $6.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 106.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.22% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | $1,683,000.00 | ★ $158,285,000.00 |
| Revenue This Year | N/A | $9.32 |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | $68.00 |
| Revenue Growth | N/A | ★ 8.46 |
| 52 Week Low | $1.34 | $5.04 |
| 52 Week High | $5.15 | $8.60 |
| Indicator | ACRS | NL |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 45.89 |
| Support Level | $4.15 | $5.55 |
| Resistance Level | $4.73 | $6.27 |
| Average True Range (ATR) | 0.24 | 0.51 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 39.64 | 13.56 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
NLI Holdings Inc, formerly known as NL Industries Inc, is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.